# MicroRNA-195-5p Targets MYB to Regulate Proliferation and Malignant Metastasis in Triple-Negative Breast Cancer via PI3K/AKT/mTOR Signaling

**Authors:** Kewei Tang, Site Bai, Qiang Zhou, Songlian Liu, Leilan Yin, Yajun Tong, Ling Long, Ludi Ou, Qinghua Yin

PMC · DOI: 10.1155/tbj/7303173 · The Breast Journal · 2025-10-16

## TL;DR

This study shows that miRNA-195-5p reduces the growth and spread of triple-negative breast cancer by targeting the MYB gene and blocking a key signaling pathway.

## Contribution

The novel finding is that miRNA-195-5p directly targets MYB to inhibit the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

## Key findings

- miRNA-195-5p is downregulated in TNBC cells compared to normal cells.
- Overexpression of miRNA-195-5p inhibits cancer cell proliferation, invasion, and migration.
- MYB overexpression counteracts the tumor-suppressive effects of miRNA-195-5p.

## Abstract

To investigate the effect of microRNA-195-5p (miRNA-195-5p) on proliferation and malignant metastasis in triple-negative breast cancer (TNBC) cells and its underlying mechanism.

Expression levels of miRNA-195-5p and MYB were determined by quantitative real-time PCR (RT-qPCR) in TNBC cells (MDA-MB-231 and BT-549) and normal human mammary epithelial cells (MCF-10A). Cell proliferation was assessed via CCK-8 assays after miRNA-195-5p overexpression or knockdown in MDA-MB-231 cells. Transwell assays evaluated cellular invasion and migration. Western blotting analyzed impacts on the PI3K/AKT/mTOR pathway. Targeting of MYB by miRNA-195-5p was confirmed using TargetScan prediction and dual-luciferase reporter assays. RT-qPCR measured MYB expression upon miRNA-195-5p modulation. Rescue experiments (co-overexpression of MYB and miRNA-195-5p) further assessed proliferation and PI3K/AKT/mTOR signaling via CCK-8 and Western blotting.

Compared to MCF-10A cells, miRNA-195-5p expression was significantly downregulated (p < 0.01), while MYB was markedly upregulated (p < 0.001) in TNBC cells. Overexpression of miRNA-195-5p inhibited MDA-MB-231 proliferation, invasion, and migration; conversely, its knockdown promoted these phenotypes. MiRNA-195-5p directly targeted and negatively regulated MYB. MYB overexpression activated the PI3K/AKT/mTOR pathway, enhancing cell proliferation. Rescue experiments indicated that MYB upregulation counteracted the tumor-suppressive effects of miRNA-195-5p and reactivated PI3K/AKT/mTOR signaling.

miRNA-195-5p suppresses proliferation and metastasis in TNBC by targeting MYB and inhibiting the PI3K/AKT/mTOR pathway.

## Linked entities

- **Genes:** MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602]
- **Diseases:** triple-negative breast cancer (MONDO:0005494)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** tumor (MESH:D009369), Malignant Metastasis (MESH:D009362), TNBC (MESH:D064726)
- **Chemicals:** CCK-8 (MESH:D012844)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF-10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), BT-549 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_1092)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12549211/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12549211/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12549211/full.md

---
Source: https://tomesphere.com/paper/PMC12549211